Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations

Uncommon epidermal growth factor receptor (EGFR) mutations in non-small lung cancer (NSCLC) are a heterogeneous group of genetic alterations that produce variable responses to EGFR-tyrosine kinase inhibitor (TKI) in patients with most of the evidence of the responses to EGFR-TKIs being based on small case studies or single case reports [1 –3]. Several studies have demonstrated that patients with uncommon EGFR mutations respond poorly to first-generation EGFR-TKIs, such as gefitinib and erlotinib, compared to patients with common EGFR mutations [2–5].

Source: Lung Cancer - November 14, 2018 Category: Cancer & Oncology Authors: Ichidai Tanaka, Masahiro Morise, Yuta Kodama, Akira Matsui, Naoya Ozawa, Sachiko Ozone, Daiki Goto, Ayako Miyazawa, Tetsunari Hase, Naozumi Hashimoto, Mitsuo Sato, Yoshinori Hasegawa Source Type: research